Meidi Utami Puteri
Overview
Explore the profile of Meidi Utami Puteri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
50
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ariestanti D, Munim A, Hartrianti P, Nadia B, Chriscensia E, Rattu S, et al.
Ultrason Sonochem
. 2025 Feb;
114:107271.
PMID: 39955874
Javanese turmeric (Curcuma xanthorrhiza Roxb.) is known for its diverse pharmacological activities due to its rich phytoconstituents, including curcuminoids and xanthorrhizol. Typically, these compounds are extracted using organic solvents, which...
2.
Puteri M, Afifah N, Mathriul A, Wicaksono F, Sugiarti M, Izzatinisa R, et al.
Adv Pharmacol Pharm Sci
. 2024 Dec;
2024:5543717.
PMID: 39734397
Antithrombotic medications, including antiplatelet agents, are standard treatments for patients with hyperlipidemia who have a high risk of developing cardiovascular disease (CVD). The ongoing exploration of new antiplatelet agents with...
3.
Saputri F, Azmi N, Puteri M, Damayanti , Novita V, Marisi G, et al.
Nutrients
. 2023 Oct;
15(20).
PMID: 37892538
Platelet activation and proprotein convertase subtilisin kexin 9 (PCSK9) play pivotal roles in the progression of atherosclerosis to cardiovascular events. It has been reported that hyperlipidemia, a well-documented risk factors...
4.
Iqbal M, Hasanah N, Arianto A, Aryati W, Puteri M, Saputri F
Adv Pharmacol Pharm Sci
. 2023 Oct;
2023:5932315.
PMID: 37860715
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial regulator of low-density lipoprotein cholesterol (LDL-c) levels, as it binds to and degrades the LDL receptor (LDLR) in the lysosome...
5.
Amalia M, Puteri M, Saputri F, Sauriasari R, Widyantoro B
Life (Basel)
. 2023 Jul;
13(7).
PMID: 37511848
Type 2 diabetes mellitus (T2DM) is a persistent metabolic condition that contributes to the development of cardiovascular diseases. Numerous studies have provided evidence that individuals with T2DM are at a...
6.
Puteri M, Azmi N, Ridwan S, Iqbal M, Fatimah T, Rini T, et al.
J Cardiovasc Dev Dis
. 2022 Aug;
9(8).
PMID: 36005422
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial factor in the development and progression of cardiovascular diseases. PCSK9 has been demonstrated to modify LDL plasma levels and increase platelet...
7.
Puteri M, Azmi N, Kato M, Saputri F
Life (Basel)
. 2022 Feb;
12(2).
PMID: 35207479
Cardiovascular diseases are the leading cause of death worldwide, with the majority of the cases being heart failure due to myocardial infarction. Research on cardiovascular diseases is currently underway, particularly...
8.
Haque M, Abdelaziz M, Puteri M, Vo Nguyen T, Kudo K, Watanabe Y, et al.
Cancers (Basel)
. 2021 Oct;
13(19).
PMID: 34638419
Transmembrane prostate androgen-induced protein (TMEPAI), also known as PMEPA1, is highly expressed in many types of cancer and promotes oncogenic abilities. However, the mechanisms whereby TMEPAI facilitates tumorigenesis are not...
9.
Wardhani B, Puteri M, Watanabe Y, Louisa M, Setiabudy R, Kato M
J Exp Pharmacol
. 2020 Mar;
12:17-26.
PMID: 32158279
Purpose: Triple-negative breast cancer (TNBC) is a refractory type of breast cancer with poor prognosis and limited choice for treatment. Previous studies had shown that TNBC has high expressions of...
10.
Amalia R, Abdelaziz M, Puteri M, Hwang J, Anwar F, Watanabe Y, et al.
Cell Signal
. 2019 Mar;
59:24-33.
PMID: 30890370
Transmembrane prostate androgen-induced protein (TMEPAI) is a type I transmembrane protein induced by several intracellular signaling pathways such as androgen, TGF-β, EGF, and Wnt signaling. It has been reported that...